Litcius/Paper detail

PL02.08 Perioperative vs Neoadjuvant Nivolumab for Resectable NSCLC: Patient-Level Data Analysis of CheckMate 77T vs CheckMate 816

Patrick M. Forde, Solange Peters, J. Donington, S. Meadows–Shropshire, P. Tran, S. Lucherini, C. Coronado Erdmann, Hao Sun, Tina Cascone

2024Journal of Thoracic Oncology48 citationsDOI

Topics & Concepts

MedicineNivolumabPerioperativeInternal medicineOncologySurgeryCancerImmunotherapyGastric Cancer Management and OutcomesCancer Immunotherapy and BiomarkersColorectal Cancer Surgical Treatments
PL02.08 Perioperative vs Neoadjuvant Nivolumab for Resectable NSCLC: Patient-Level Data Analysis of CheckMate 77T vs CheckMate 816 | Litcius